Esperance Pharmaceuticals, Inc. is currently conducting a multi-center Phase 1 clinical trial testing EP-100 as a treatment for patients with LHRH receptor-expressing solid tumors. The goals of the Phase 1 trial are to evaluate EP-100’s safety, pharmacokinetics, and potential efficacy.
For more information about the trial or how to enroll, please visit www.clinicaltrials.gov ("search for clinical trials", "EP-100 or Esperance") or contact us.